Similar, crizotinib can be administered to patients with ROS1-rearranged NSCLC that do not express ALK or c-Met, as LDK378 (Ceritinib) and AP26113 ALK inhibitors demonstrate clinical efficacy on crizotinib-resistant NSCLC tumours with increased abundance of IGF-1R and ROS proteins [82,83,84]. The gene discussed is MET; the disease is neoplasm.